KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to -$331.0 million.

  • Biomarin Pharmaceutical's Cash from Investing Activities fell 1948.42% to -$331.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.4 million, marking a year-over-year decrease of 5958.02%. This contributed to the annual value of $136.5 million for FY2024, which is 222.70% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Cash from Investing Activities stood at -$331.0 million, which was down 2,528.36% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Cash from Investing Activities registered a high of $90.5 million during Q2 2024, and its lowest value of -$331.0 million during Q3 2025.
  • Over the past 3 years, Biomarin Pharmaceutical's median Cash from Investing Activities value was -$16.2 million (recorded in 2024), while the average stood at -$31.5 million.
  • In the last 5 years, Biomarin Pharmaceutical's Cash from Investing Activities skyrocketed by 224.01% in 2022 and then tumbled by 1,948.42% in 2025.
  • Biomarin Pharmaceutical's Cash from Investing Activities (Quarterly) stood at -$55.4 million in 2021, then rose by 1.28% to -$54.7 million in 2022, then fell by 18.74% to -$65.0 million in 2023, then soared by 217.61% to $76.4 million in 2024, then tumbled by 1,948.42% to -$331.0 million in 2025.
  • Its last three reported values are -$331.0 million in Q3 2025, -$12.6 million for Q2 2025, and -$28.2 million during Q1 2025.